Adjunctive povidone-iodine for Acanthamoeba keratitis: a randomized trial
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
The aim of this study was to determine the antiamoebic efficacy of povidone-iodine when used as an adjunct to topical biguanide therapy for Acanthamoeba keratitis. Patients with smear- or culture-positive Acanthamoeba keratitis received topical chlorhexidine 0.04%, half-hourly for 2 days, then hourly for days 3–6, then eight times per day for days 7–28. Participants were randomized in a 1:1 ratio to receive either adjunctive topical povidone-iodine at the same frequency as chlorhexidine or no additional therapy (i.e., control group). Povidone-iodine was initially administered as a 2.5% solution but was reduced to a 1% solution after several reports of intolerance. The primary outcome was Acanthamoeba growth from the culture of corneal scrapings at 1, 2, and 4 weeks after randomization, as assessed by laboratory staff masked to treatment allocation. Of 49 patients enrolled, 25 were randomized to adjunctive povidone-iodine (mean age 48 [SD 16] years; 32% female) and 24 to control (mean age 43 [15] years; 33% female). Four (16%) participants discontinued 2.5% povidone-iodine prematurely due to intolerance. The proportion of participants with a positive culture during the initial 4 weeks of antiamoebic treatment was not significantly different in the povidone-iodine group (6/18 [33%] at 4 weeks) and control group (5/16 [31%] at 4 weeks) (RR 0.90, 95%CI: 0.35–2.29; P = 0.82). When used as an adjunctive to standard biguanide therapy, povidone-iodine did not markedly accelerate the clearance of Acanthamoeba organisms from the corneal surface over the initial month of therapy. This study is registered with ClinicalTrials.gov as NCT03484507 .
Fields of Study & Subjects
Ocular Infections and Treatments
Legionella and Acanthamoeba research
Amoebic Infections and Treatments
Publication details
- Journal / source
- Antimicrobial Agents and Chemotherapy
- Volume
- 70
- Issue
- 5
- Pages
- e0151225–e0151225
- Publication date
- 31 March 2026
- Language
- EN